Interleukin 35 Protein (IL35) (AA 23-215, AA 23-228) (Fc Tag)

Catalog No. ABIN6253338

This Recombinant Interleukin 35 protein is produced in CHO Cells.

Quick Overview for Interleukin 35 Protein (IL35) (AA 23-215, AA 23-228) (Fc Tag) (ABIN6253338)

Target: Interleukin 35 (IL35)

Protein Type: Recombinant

Origin: Mouse

Source: CHO Cells

Purity: >98 % (SDS-PAGE)

Product Details

Protein Characteristics: AA 23-215, AA 23-228

Purification tag / Conjugate: This Interleukin 35 protein is labelled with Fc Tag.

Purpose: IL-35 (mouse):Fc (human) (rec.)

Specificity: A soluble dimeric fusion protein consisting of the extracellular domain of mouse IL12a subunit (aa 23-215) is fused to the Fc region of human IgG1, and the mouse Ebi3 subunit (aa 23-228) linked to IL12a by disulfide bonds.

Characteristics: Protein. A soluble dimeric fusion protein consisting of the extracellular domain of mouse IL12a subunit (aa 23-215) is fused to the Fc region of human IgG1, and the mouse Ebi3 subunit (aa 23-228) linked to IL12a by disulfide bonds. Source: CHO cells. Endotoxin content: <0.06EU/μg protein (LAL test, Lonza). Lyophilized from 0.2μm-filtered solution in PBS. Purity: >98 % (SDS-PAGE). Interleukin-35 (IL-35) is a novel IL-12 family cytokine produced by regulatory T cells (Treg) but not by resting or activated effector T cells (Teff). IL-35 is a heterodimeric protein composed of EBI3 (Epstein-Barr-Virus-induced gene 3) and IL-12a (p35). EBI3 is a downstream target of Foxp3, a transcription factor required for Treg-cell development and function, and thus Treg-cell restriction of IL35 occurs. Regulatory T cells are essential for maintaining self tolerance and preventing autoimmunity, and IL-35 is identified as a molecule that mediates the immune suppression function of Treg-cell. As an inhibitory cytokine, IL-35 induces proliferation of Treg-cell populations but suppresses Th17 cell development. Studies in mice show the absence of either IL-35 chain from Treg-cell reduces the cells' ability to suppress inflammation using an experimental model for inflammatory bowel disease. IL-35 is suggested as a potential target of immunotherapy. Recently, insufficient IL-35 levels were shown to play a pivotal role in the development of type 1 diabetes (T1D) and autoimmune diseases.

Endotoxin Level: <0.06EU/μg protein (LAL test, Lonza).

Biological Activity Comment: Bioactivity was measured in a cell proliferation assay of Con A activated mouse splenocytes.

Application Details

Restrictions: For Research Use only

Handling

Format: Lyophilized

Concentration: Lot specific

Buffer: Lyophilized from 0.2μm-filtered solution in PBS.

Handling Advice: Avoid freeze/thaw cycles.

Storage: 4 °C,-20 °C

Storage Comment:

Short Term Storage: +4°C

Long Term Storage: -20°C

Use & Stability: Stable for at least 1 year after receipt when stored at -20°C. Working aliquots are stable for up to 3 months when stored at -20°C.

Target Details

Target: Interleukin 35 (IL35)

Alternative Name: IL-35

Background:

Alternate Names/Synonyms: Interleukin-35

Product Description: Interleukin-35 (IL-35) is a novel IL-12 family cytokine produced by regulatory T cells (Treg) but not by resting or activated effector T cells (Teff). IL-35 is a heterodimeric protein composed of EBI3 (Epstein-Barr-Virus-induced gene 3) and IL-12a (p35). EBI3 is a downstream target of Foxp3, a transcription factor required for Treg-cell development and function, and thus Treg-cell restriction of IL35 occurs. Regulatory T cells are essential for maintaining self tolerance and preventing autoimmunity, and IL-35 is identified as a molecule that mediates the immune suppression function of Treg-cell. As an inhibitory cytokine, IL-35 induces proliferation of Treg-cell populations but suppresses Th17 cell development. Studies in mice show the absence of either IL-35 chain from Treg-cell reduces the cells' ability to suppress inflammation using an experimental model for inflammatory bowel disease. IL-35 is suggested as a potential target of immunotherapy. Recently, insufficient IL-35 levels were shown to play a pivotal role in the development of type 1 diabetes (T1D) and autoimmune diseases.

NCBI Accession: NP_032377